A Multimodal Imaging Study of Dopamine in Early Psychosis (MISDEP)

The development of new treatments for psychosis, a psychiatric condition that is prevalent and highly disabling despite antipsychotic medications, has been limited, in part, by a lack of information from brain imaging studies during the period that leads to the development of psychotic symptoms. In this project the investigators will use Positron Emission Tomography (PET) and neuromelanin-sensitive magnetic resonance imaging (NM-MRI) to examine a brain chemical that is involved in schizophrenia called dopamine and where it first becomes abnormal. The investigators will use multimodal PET/MR imaging (i.e., [11C]raclopride w/MPH challenge and NM-MRI) in the same CHR patients. The investigators will recruit 115 clinical high risk individuals. All subjects will undergo [11C]raclopride w/methylphenidate challenge and neuromelanin-MRI imaging along with clinical assessments. Patients will be followed every 3 months for two years or until conversion to psychosis, whichever comes first, to assess for conversion to psychosis and clinical outcomes.

Study Overview

• Status: Not yet recruiting
• Conditions: Clinical High Risk for Psychosis (CHR)
• Intervention / Treatment: Drug: Methylphenidate (MPH); Drug: [11C]raclopride

Detailed Description

A large body of evidence suggests that abnormal striatal dopamine (DA) transmission is a key pathophysiological phenomenon in psychosis, mainly within the associative striatum (AST). However, it remains unclear where striatal DA abnormalities in psychosis start and whether they can be turned into a biomarker for development of psychotic illness. Early studies in individuals at clinical high-risk for psychosis (CHR) demonstrated that patients had higher [18F]DOPA uptake (i.e., DA synthesis capacity) in the AST compared to healthy control subjects (HC). One study reported that CHR individuals who developed a syndromal psychotic disorder had higher [18F]DOPA uptake than CHR individuals who did not progress. However, more recent work in larger samples has not replicated either finding. The investigators recently completed a feasibility study in which the investigators used [11C]-(+)-PHNO w/methylphenidate (MPH) challenge to examine intrasynaptic DA transmission in 14 CHR individuals and 14 HCs. The investigators found that intrasynaptic DA transmission was significantly elevated in the limbic/ventral striatum (VST), and not in any other ROI, in CHR individuals compared to HC. There was a strong correlation between intrasynaptic DA transmission in VST and total negative symptoms in the CHR group in which greater displacement was related to less negative symptoms. CHR subjects experienced no change in positive symptoms with MPH challenge, which demonstrates the safety of this technique. Additionally, our preliminary data with neuromelanin sensitive MRI (NM-MRI), a MR technique of measuring NM, a metabolite of DA, in different presynaptic nuclei (the substantia nigra [SN; the ventromedial portion of which projects to the AST] and ventral tegmental area [VTA; which projects to the VST]), demonstrate positive relationships between the contrast-to-noise ratio (CNR) of NM-MRI in the SN and positive symptoms in CHR and SCZ subjects. Taken together, these findings may reflect: 1) that striatal DA abnormalities in early psychosis progress in a temporo-spatial manner from VST to AST; 2) a clinical pattern in which negative symptoms are related to limbic DA transmission and positive symptoms reflect DA function in associative regions; 3) differences in biomarker (i.e., PHNO w/MPH challenge, NM-MRI, [18F]DOPA). This proposal will aim to advance the understanding of the nature, topography, and timing of striatal DA alterations in early psychosis by using multimodal PET/MR imaging (i.e., [11C]raclopride w/MPH challenge and NM-MRI) in the same CHR patients. The investigators will recruit 115 CHR individuals. All subjects will undergo [11C]raclopride w/MPH and NM-MRI imaging along with clinical assessments. Patients will be followed every 3 months for two years or until conversion to psychosis, whichever comes first, to assess for conversion to psychosis and clinical outcomes. Clarifying the nature, timing, and topography of DA abnormalities in early psychosis will greatly inform translational studies and could provide support for alternative initial therapeutic interventions to prevent progression in early psychosis.

• Study Type: Interventional
• Enrollment (Estimated): 115
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Ragy Girgis, MD; Phone Number: 646-774-5553; Email: ragy.girgis@nyspi.columbia.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Males or females between 18 and 30 years old
2. Capacity to give informed consent
3. Clinical High Risk (i.e., APSS, GRDS, BIPS)
4. Antipsychotic free for 3 weeks before the PET scan
5. Clinically stable enough for the study

Exclusion Criteria:

1. Any substance use disorder, of any severity, within the previous month (before PET scan; not including nicotine or caffeine)
2. Any current use of substance of abuse besides THC/marijuana/cannabis/nicotine/caffeine (on day of PET only)
3. Daily tobacco use
4. Pregnancy
5. Lactation
6. Presence of insulin-dependent diabetes
7. IQ < 70 (i.e., WTAR < 6)
8. Acute risk for suicide (i.e., score of 4-5 within the previous month or 6 within the previous 3 months on the CSSRS) or violence, or history of severe violent behavior that may be exacerbated by methylphenidate
9. Presence of metallic objects in the body
10. Lifetime exposure to radiation in the workplace (i.e., being badged for radiation exposure), or exposure to radiation in the context of research protocol within the previous year that exceeds annual limits
11. More than one risk factor for coronary artery disease (e.g., smoking, hyperlipidemia, sedentary lifestyle)
12. Hypertension
13. Presence of clinically significant brain abnormalities. [For PET Scan Only]
14. Previous adverse reaction to stimulants that would preclude receiving methylphenidate
15. Presence or positive history of any cardiovascular disease, medical or neurological condition that would preclude methylphenidate administration or participation in this study
16. A history of bipolar disorder Type 1, or any history of syndromal psychosis
17. Lack of effective birth control

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Methylphenidate; Each subject will receive one oral dose of 60mg methylphenidate in between 2 PET scans with [11C]raclopride.	Drug: Methylphenidate (MPH); Each participate will receive one oral dose of 60mg methylphenidate.; Drug: [11C]raclopride; This is the radiotracer that will be used along with methylphenidate to quantify dopamine transmission in this study. It is experimental and used for imaging purposes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dopamine transmission	Delta BPND of [11C]raclopride in the Associative Striatum	From the first (before methylphenidate) to the second PET scans (one hour after methylphenidate) on Day 1 of the study
Conversion to syndromal psychosis	Development of a '6' on a P symptom of the SIPS	From administration of the study drug to either conversion to a syndromal psychotic disorder or 24 months, whichever comes first.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Positive Symptoms	Total P symptom score on the SIPS	At time zero before administration of methylphenidate
Negative Symptoms	Total N symptom score on the SIPS	At time zero before administration of methylphenidate
Dopamine Transmission in the ventral striatum	Delta BPND ([11C]raclopride) in the Ventral striatum	From the first (before methylphenidate) to the second PET scans (one hour after methylphenidate) on Day 1 of the study

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Baseline dopamine	Neuromelanin MRI in midbrain at baseline	At time zero before administration of methylphenidate
Change in positive symptoms	Change in total SIPS positive symptoms	From time zero before administration of methylphenidate to either conversion to a syndromal psychotic disorder or 24 months, whichever comes first.
Change in negative symptoms	Change in total N symptoms on the SIPS	From time zero before administration of methylphenidate to either conversion to a syndromal psychotic disorder or 24 months, whichever comes first.

Collaborators and Investigators

• Sponsor: New York State Psychiatric Institute
• Collaborators: National Institute of Mental Health (NIMH); Columbia University; Stony Brook Medicine

Publications and helpful links

General Publications

• Girgis RR, Slifstein M, Brucato G, Kegeles LS, Colibazzi T, Lieberman JA, Abi-Dargham A. Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study. Mol Psychiatry. 2021 Jun;26(6):2504-2513. doi: 10.1038/s41380-020-00934-w. Epub 2020 Nov 5.

Study record dates

Study Major Dates

• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): October 1, 2029
• Study Completion (Estimated): October 1, 2030

Study Registration Dates

• First Submitted: May 8, 2025
• First Submitted That Met QC Criteria: May 15, 2025
• First Posted (Actual): May 18, 2025

Study Record Updates

• Last Update Posted (Actual): July 14, 2026
• Last Update Submitted That Met QC Criteria: July 11, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: clinical high risk for psychosis
• Additional Relevant MeSH Terms: Schizophrenia Spectrum and Other Psychotic Disorders; Psychotic Disorders; Mental Disorders; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Carboxylic Acids; Piperidines; Acids, Carbocyclic; Phenylacetates; Methylphenidate
• Other Study ID Numbers: 8361; 1R01MH128330 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Data will be shared via the NIH data archive.
• IPD Sharing Time Frame: Data will be shared after the study has been completed, as per NIH guidelines.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No